ABSTRACT
The lack of medication to suppress coronavirus infections is a main reason for the dramatic course of the COVID-19 pandemic. There is an urgent need to identify suitable coronavirus drug targets and corresponding lead molecules. Here we describe the discovery of a class of coronavirus inhibitors acting on nsp15, a hexameric protein component of the viral replication-transcription complexes, endowed with immune evasion-associated endoribonuclease activity. SAR exploration of these 1,2,3-triazolo fused betulonic acid derivatives yielded lead molecule 5h as a strong inhibitor (antiviral EC50: 0.6 μM) of human coronavirus 229E replication. An nsp15 endoribonuclease active site mutant virus was markedly less sensitive to 5h, and selected resistance to the compound mapped to mutations in the N-terminal part of nsp15, at an interface between two nsp15 monomers. The biological findings were substantiated by the nsp15 binding mode for 5h, predicted by docking. Hence, besides delivering a distinct class of inhibitors, our study revealed a druggable pocket in the nsp15 hexamer with relevance for anti-coronavirus drug development.
Competing Interest Statement
The authors have declared no competing interest.
ABBREVIATIONS USED
- CC50
- 50% cytotoxic concentration
- CoV
- coronavirus
- COVID-19
- coronavirus disease 2019
- CPE
- cytopathic effect
- DAPI
- 4′,6-diamidino-2-phenylindole
- EndoU
- endoribonuclease
- FIPV
- feline infectious peritonitis virus
- HEL
- human embryonic lung
- MERS
- Middle East respiratory syndrome
- MHV-A59
- mouse hepatitis virus A59
- MTS
- 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
- nsp
- non-structural protein
- p.i.
- post-infection
- RTC
- replication-transcription complex
- SARS
- severe acute respiratory syndrome
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- TCID50
- 50% tissue culture infective dose